– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part ...
Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal ...
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results